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Abstract. Miltefosine, an effective oral treatment of visceral leishmaniasis (VL), was selected in May 2005, by the
governments of India, Nepal, and Bangladesh for the elimination of VL. However, abnormally high treatment failure rates
reported in patients in Bangladesh, given a miltefosine generic product (“Miltefos”, Popular Pharmaceuticals Ltd.) during
2008, led the World Health Organization (WHO) to procure this formulation for quality testing. Proton (1H) and phospho-
rous (31P) nuclear magnetic resonance (NMR) analyses of the Miltefos™ capsules did not give the peaks defined for
ImpavidoÒ, the quality assured VL treatment product from Aeterna Zentaris. Contents of capsules of ImpavidoÒ yielded
expected peaks for miltefosine (m/z 408.33 for the protonated parent ion and m/z 183.99 plus m/z 124.8 the fragment ions)
that were absent in the Miltefos™ capsules. Furthermore, testing using an in vitro Leishmania donovani intracellular
amastigote—macrophage model, yielded EC50 values of between 2.55 and 4.06 mg/mL and 3.02 to 5.92 mg/mL for extracts
from the ImpavidoÒ capsules and the miltefosine standard, respectively. Lack of significant anti-leishmanial activity of
Miltefos™ capsules was identified in this assay even at concentrations up to 100 mg/mL. Capsules of Miltefos™ were
classified as falsified (absence of stated active pharmaceutical ingredient) by three methods—NMR and mass spectrometry
analysis and bioassay.
INTRODUCTION
The leishmaniases are a group of neglected tropical diseases
caused by parasites of the genus Leishmania. The main disease
manifestations are cutaneous leishmaniasis (CL) and visceral
leishmaniasis (VL). Active VL has a high fatality rate in almost
all cases and requires treatment with anti-leishmanial drugs.
Recent estimates for VL suggest between 200,000 and 400,000
cases and 20,000 and 40,000 deaths per year worldwide with
over 90% of cases occurring in India, Bangladesh, Sudan,
South Sudan, Brazil, and Ethiopia.1 Current drugs for VL
include pentavalent antimonials, amphotericin B (formulated
as salt with deoxycholate in FungizoneÒ or in a liposomal form
as AmBisomeÒ), miltefosine, and paromomycin. Multi-drug
therapy by co-administration regimes is also being pursued
as an improved treatment strategy for VL.2
Miltefosine, originally developed as an anticancer drug, is
the first effective oral treatment of VL and CL. It was deter-
mined to be safe and effective for the treatment of Indian VL
following a trial, in which 282 of 299 (94%) patients were cured
with an oral dose of 2.5 mg/kg of miltefosine given daily for
28 days as monotherapy.3 It was then registered in India
for oral treatment of VL in March 2002.4 The drug is well-
tolerated, except for mild gastrointestinal side effects, but its
teratogenic potential hampers its general use in the clinic, par-
ticularly for women of childbearing age. It has a long elimina-
tion half-life and accumulates in the body during treatment.5
Miltefosine (currently available through Paladin Laboratories,
Inc., Montreal, Canada) under the trade name ImpavidoÒ, was
adopted by the governments of India, Nepal, and Bangladesh
as an oral treatment of VL in the program to eliminate this
disease by 2015.6 As part of the elimination program, and
to improve procurement of this necessary intervention, the
Bangladesh authorities identified a local company (Popular
Pharmaceuticals Ltd., Dhaka, Bangladesh) that manufactured
generic miltefosine, “Miltefos”, for supply.
“Miltefos” was introduced as a first-line therapy for VL in
Bangladesh in 2008. Bangladesh authorities and World Health
Organization (WHO) were reporting unexpected levels of
treatment failures shortly after its introduction in 2008, a dif-
ferent clinical response to that determined in India and
Nepal.4,7 Both “Miltefos” and ImpavidoÒ were administered
simultaneously to patients and it became immediately apparent
that the group on “Miltefos” did not show the anticipated
treatment response. As part of the investigation to establish
the basis for this difference, samples of “Miltefos” were sent
to the Academic Medical Center, University of Amsterdam
and to the London School of Hygiene and Tropical Medicine
(by WHO). The group in Amsterdam characterized represen-
tative drug samples from batches labeled 10 mgmiltefosine and
50 mg miltefosine using a liquid chromatography–tandem mass
spectrometry (MS/MS) methodology developed with a sensi-
tivity as low as 4 ng/mL in human plasma.8,9 Further studies
using second drug samples and examination of blood samples
from five patients, confirmed that 1) no active pharmaceutical
ingredient could be identified in the “Miltefos” batches and,
2) miltefosine could not be detected in the blood of the patients
who had been administered “Miltefos” capsules.10
We describe here the results of studies performed on
Miltefos™ batches received by WHO in 2008 at the same time
as those sent to the group in Amsterdam. Our data, acquired
using nuclear magnetic resonance (NMR) spectroscopy, mass
spectrometry (MS), and bioassay analyses, supports the findings
of Dorlo and others8,9 and further characterizes this falsified
drug by complementary methodologies.
MATERIALS ANDMETHODS
Samples. The WHO received in 2008, requests from their
South East Asia Regional Office (SEARO), Delhi, and the
Directorate General of Health Services of Bangladesh to test a
generic miltefosine formulation produced by Popular Pharma-
ceuticals Ltd., for quality issues. The WHO SEARO sampled a
number of blister packs randomly fromwarehouses but without
a precise methodology. Three sealed packs were collected from
the subdistrict health centers (upazila health level) where the
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drugs were supplied by the program for patient treatment.
The samples were collected jointly by the Representatives of
Directorate of Health, WHO-Bangladesh, Popular laborato-
ries, and Directorate of Drug Administration and sent to
WHO-Geneva by the Director General of Health Services.
WHO-Geneva coordinated the work with the London School
of Hygiene and Tropical Medicine (LSHTM) and Bangladesh
authorities. Miltefos™ capsules were received from WHO
SEARO and the WHO Department of Neglected Tropical
Diseases and Department of Essential Medicines and Pharma-
ceutical Policies, Geneva.
ImpavidoÒ capsules (containing 50 mg and 10 mg miltefosine,
batch nos. 8J7717 and 8H7859, respectively) and the active phar-
maceutical ingredient (API) miltefosine (D-18506, batch no.
986356) were a gift from Paladin Laboratories Inc. (Montreal,
Canada). Upon arrival capsules and API were stored at an air
conditioned laboratory (21°C).
Chemicals.Methanol (99.8 +% (GLC) and water were from
Thermo Fisher Scientific, Hemel Hempstead, UK. Deuterated
chloroform the solvent used for NMR spectroscopy and
tetramethylsilane the chemical shift reference were purchased
from Sigma-Aldridge, Dorset, UK. Both high performance
liquid chromatography grade methanol and water of purity
grade were from Thermo Fisher Scientific. Giemsa’s stain
(improved R66 solution Gurr) was purchased from VWR, East
Grinstead, West Sussex, UK, RPMI-1640 medium from Sigma,
UK, and fetal calf serum (FCS) from Harlan-Sera Laboratory,
Leicestershire, UK.
1H and 31P NMR spectroscopy analysis. Proton and phos-
phorous (1H and 31P) are high-resolution atomic nuclei, both
having spin quantum number I = 1/2. An advantage of 1H
NMR is that it is more sensitive than 31P by a factor about 10.
However, 31P has a greater chemical shift range than 1H.
In addition, a phosphorous-containing molecule typically has
considerably more chemically distinct proton environments
than it has phosphorous environments. Therefore, 1H NMR
spectra from such molecules are inherently considerably more
complex than 31P spectra, but at the same time the 1H spectra
have a far greater overall information content. In this case, as
the molecule of miltefosine has a phosphorous atom it was
judged to be appropriate to analyze using 31P NMR.
Miltefosine (API reference compound) and the contents
of the capsules were dissolved in deuterated chloroform
(CDCl3), which dissolves the API but not the excipients. The
solute filtered through ordinary tissue paper and transferred
into NMR tubes followed with the addition of the chemical shift
reference (TMS; tetramethylsilane). The chemical shift refer-
ence for 31P spectra was external 85% H3PO4. The tube was
then inserted into the instrument—Bruker Avance 400 NMR
spectrometer (Coventry, UK) measuring the proton (1H) and
phosphorous (31P) spectra at 400 and 162 MHz, respectively.
Extraction of capsule content and preparation of stock
solutions for MS and bioassay analysis. Capsules of Miltefos™
and ImpavidoÒ were opened and the contents emptied into pre-
weighed glass vials. The weight of capsule contents was recorded
and 5 mL of a 1:1 (v/v) mixture of methanol and water added.
Vials were briefly shaken and placed in a cooled ultrasound
water bath for 30 minutes with 2–3 times vortexing in between.
Vials were left to stand in the air conditioned laboratory (21°C)
for 30 minutes after which 2 mL of solutions were transferred
to Eppendorf tubes. Tubes were centrifuged at 13,000 rpm
for 10 minutes (SANYO; Micro Centaur; MSE, London, UK)
and the supernatant transferred to new Eppendorf tubes. One
aliquot was filter sterilized by passing the solution through a
MinisartÒ syringe end filter (pore size 0.2 mm) and used as stock
solution for the bioassay. The other aliquot was used in liquid
chromatography mass spectrometry analysis. The API stock was
prepared in the same solvent as capsule extracts.
MS analysis and data processing. Mass spectrometry full
scan and MS/MS analyses were performed on the Thermo
Finnigan LCQ ion trap instrument with an electron spray ion-
ization (ESI) source (THermoFinnigan, Hemel Hempstead,
UK). The ESI source was operated in the positive ion mode
with the following operating conditions optimized for milte-
fosine by infusing a solution (2 mg/mL reference standard
in methanol/water; v/v; 1:1) using the syringe pump at a flow
rate of 2.5 mL/min; transfer capillary temperature 220°C, spray
voltage 4.55 kV, capillary voltage 3.29 V, and sheath gas flow
30 (arbitrary units). Nitrogen was used as the nebulizing gas
(by Peak, Scientific, Inchinnan, Scotland, UK; generator). Data
acquisition and processing was performed using Xcalibur soft-
ware (version 2.0.7 SP1). The cumulative scans were recorded
over a mass range ofm/z 110–430 for 3 minutes to be sure that
all the ions in the sample were included in the spectrum. Solu-
tions were directly infused to the system using the syringe
pump. The probe was washed between each sample analysis
first with water and then with methanol to ensure that there
was no carryover of the previous sample.
Drug activity evaluation. The anti-leishmanial activity of
capsule extracts and API was evaluated in a standard assay
as described previously.11 Briefly, mouse peritoneal macro-
phages (PEMs) were harvested from CD1mice (Charles River,
Margate, UK) by lavage 24 hours after intraperitoneal injec-
tion of 2% soluble starch in PBS (both from Sigma). Macro-
phages were plated in Lab-tek 16-well chamber slides (VWR)
at a density of 5 + 104 cells/well in RPMI 1640 medium plus
10% hi-FCS. Macrophages were left to adhere overnight at
37°C, 5% CO2, and infected with freshly harvested Leishmania
donovani amastigotes (MHOM/ET/67/HU3 in experiment 1 and
MHOM/IN/80/DD8 in experiment 2) at an infection ratio of
1 macrophage: 5 amastigotes. After incubating cultures over-
night at 37°C, 5% CO2 non-phagocytosed amastigotes were
gently washed off andmiltefosine added at the final concentra-
tions of 100, 20, 4, and 0.8 mg/mL. A 4-point dilution series
spanning the concentration ranges used here was based on
knowledge of miltefosine activity and toxicity towards host
cells. Each concentration was tested in quadruplicate. Controls
received serum substituted medium only or serum substituted
medium containing 0.5%, 0.1%, and 0.02% (v/v) methanol.
Infected macrophages were incubated with drug dilutions for
a total of 3 days at 37°C, 5%CO2.
At assay endpoint, slides were fixed with 100% methanol
and stained with 10% Giemsa in water. The average of the
quadruplicates of cultures receiving medium only was taken to
serve as 100% control against which the percentage inhibition
of infected macrophages in treated cultures was calculated.
Effective concentrations at the 50% level (EC50 values) were
estimated with the non-linear sigmoidal curve-fitting Levenburg
Marquardt algorithm (Microsoft xlfit, ID Business Solution,
Guildford, Surrey, UK). Dose responses were additionally
checked manually from the raw data (percentage infected mac-
rophages/inhibition) to confirm fitness of data. Toxicity against
macrophages was noted when no macrophages were present
in a well or macrophage morphology and/or number clearly
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changed when compared with untreated controls. All experi-
ments involving animals were conducted under license in accor-
dance with UKHome Office License no. PPL5937.
RESULTS
Proton nuclear magnetic resonance spectroscopic 1H NMR
spectra.Miltefosine (hexadecylphosphocholine, Figure 1, shows
the numbering of the scheme of atoms of the molecule used to
describe the NMR spectral peaks) reference standard was
dissolved completely in CDCl3 to give a clear solution and
the spectral peaks, which matched those resulting from the
extracts of ImpavidoÒ (50 and 10 mg miltefosine) as shown
on Figure 2. The 1H NMR spectrum of the Miltefos™ cap-
sules (Figure 3) does not show any signals from a phospho-
choline group, viz CH2(1¢) at d 3.8, CH2(2¢) at d 4.25, N(CH3)3
at d 3.35. In addition, there is no signal at d 3.8 due to CH2(1)
of the hexadecyl chain. Instead, a new signal is seen at d 2.35
(integration for CH2). The presence of the phosphocholine
group in the is seen in the 31P NMR spectrum of the ImpavidoÒ
capsules Figure 4 but is lacking in the spectrum from the
Miltefos™ capsules (Figure 5).
It is of interest to determine the nature of the compound(s)
detected in the 1H NMR spectrum of the Miltefos™ capsules.
The spectrum in Figure 3 shows the signals expected of a
hexadecyl derivative C16H33X, with the signal of the terminal
CH2 group (–CH2–X) at d 2.35. There are no other significant
1H NMR signals to be considered. Inspection of 1H NMR
databases† ‡indicates that –X is unlikely to be an oxygen
substituent or halogen because the –CH2X
1H NMR signal
(d 2.35) is too low in frequency. The exact nature of X is not
certain, as there is no information available on the procedures
followed for the production of Miltefos™ capsules. Candidate
structures for the substituent X, based upon the position
of the CH2X
1H NMR signal, are 1) X = SH (−CH2SH at‡
d 2.56 in hexadecyl mercaptan) and 2) X = (C=O) C16H33
(–CH2CO– at† d 2.4 in similar di-n-alkylketones). However,
a very good match occurs for X = CO2H; –CH2CO2H at d
2.35–2.36 in hexadecanoic acid (palmitic acid) C15H31CO2H
and heptadecanoic acid§ C16H33CO2H both of which occur
naturally in milk and certain meat fats. Palmitic acid has a
molecular weight of 256.42 and a peak is seen on the MS at
278.90 (Figure 8A), which may be thus assigned to ([M + Na]+).
MS (full scan and MS/MS) analysis. The proposed frag-
mentation pattern of the protonated ion of miltefosine is
depicted in Figure 6. A full scan (110 – 450 m/z) spectrum
will detect the presence or absence of miltefosine in the cap-
sules by checking for the anticipated protonated parent ion
[M + H]+ at m/z 408.33 and the sodium adducts [M + Na]+ at
m/z 430.25 in the solutions (Figure 7A). (The sodium ion Na+
detected in the ESI trap is postulated to originate from the
solvents and/or glass ware used). The protonated parent ion
was then induced to fragment in the collision cell. The MS/MS
fragment ion spectrum will result in the m/z 183.99 fragment
that corresponds to the loss of the C16− alkyl chain and fur-
ther cleavage of this precursor fragment ion results in the
product ion at m/z 124.8 (Figure 7B).
Dilutions of the reference standard (2 mg/mL) were carried
out using the solvent (methanol: water; v/v; 1:1) down to
0.1 mg/mL and infused into the probe using the syringe pump
to determine the limit of detection of our method.
Direct mass spectral analysis was used to detect the pres-
ence or absence of the compound – miltefosine, the active
ingredient as stated on the labels of generic miltefosine
capsules from ImpavidoÒ (Figure 8A and B) and Miltefos™
Figure 1. Chemical structure with the numbering scheme of atoms of the miltefosine molecule used in the description of the nuclear magnetic
resonance (NMR) spectral peaks plus the chemical shift (d) for the protons and their position on the molecule.
† Human Metabolome Database www.hmdb.ca.
‡ www.molbase.com.
§ Normal errors, ±5%, on integration of 1H NMR signals accommo-
dates either structure.
Figure 2. The 1H NMR (CDCl3, 400 MHz) spectra of an extract
of ImpavidoÒ, 50 mg miltefosine capsules show position of the peaks
and their assignment to the protons in the structure of miltefosine
(see Figure 1) d 0.90, 3H, t, CH3(16), d 1.25, 26 H, bs, CH2(3–15),
d 1.60, 2H, m, CH2(2), d 3.35, 9H, s, (CH3) 3 N
+, d 3.80, 4H, m,
CH2(1 and 1¢), d 4.25, 2H,b s, CH2(2¢).
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(Figure 8A and B). The presence of the protonated parent
ion peak at m/z 408.33 on the full-scan analyses and of m/z
183.99 and m/z 124.8 on the MS/MS product ion scan were
used to confirm the presence or absence of the active ingredi-
ent – miltefosine in the capsules. Summary results of the NMR
and MS analyses of the capsules of Miltefos™ and ImpavidoÒ
are shown in Table 1.
Anti-leishmanial activity of extracted capsule contents and
API.Drug assays were validated through the use of reference
standards (API prepared in two different stock concentra-
tions corresponding to the stocks theoretically obtained from
capsule extracts), confirmed to give EC50 values in agreement
with known anti-leishmanial activity of miltefosine.11 Dose
response curves were obtained for extracts from ImpavidoÒ
capsules labeled to contain 50 and 10 mg miltefosine, which
allowed the estimation of EC50 values. These were consistent
with values obtained from the reference standard and within
the expected range of known miltefosine activity in vitro.
Values at the EC50 level ranged from 2.68 mg/mL to 4.02 mg/mL
(corresponding to 6.58 to 9.86 mM) against the L. donovani
strain originating from Ethiopia (experiment 1) and from
2.55 mg/mL to 4.06 mg/mL (corresponding to 6.26 to 9.96 mM)
against the Indian L. donovani strain (experiment 2). Corre-
sponding values for the respective reference standards were
4.99 mg/mL and 3.79 mg/mL for the Ethiopian strain and
5.92 mg/mL and 3.02 mg/mL for the Indian strain. In contrast
no significant reduction in the number of infected macrophages
was obtained with extracts from Miltefos™ capsules and no
EC50 values could be determined. EC50 values are summarized
in Table 2. The highest concentration of 100 mg/mL produced
toxicity towards macrophages when exposed to API or extracts
from ImpavidoÒ capsules as judged by a reduction in the
number of macrophages/well. At this concentration toxicity
towards the host cell was expected for the API and extracts
from capsules containing the stated amount of miltefosine. No
toxicity was observed for cultures exposed to extracts from
Miltefos™ capsules.
DISCUSSION
Drug quality issues have been raised previously over two
types of the drugs currently used for the treatment of both VL
and CL.2 The pentavalent antimonials have been used for the
treatment of VL since 1937, CL since 1943, and for the mucocu-
taneous form of the disease since 1962. Despite this the chemi-
cal structure of the two commercially available forms, sodium
stibogluconate (PentostamÒ or SSG) and N-Methylglucamine
antimoniate (GlucantimeÒ) have only recently been determined
by Frezard and colleagues.12,13 Sodium stibogluconate appears
as a complex mixture of polymeric forms, with batch-to-batch
variation and solutions containing 32–34% pentavalent anti-
mony (SbV). Methylglucamine antimoniate has an SbV content
that varies around 28% between batches. The major moieties
of this oligomeric drug are Sb(v)—ligand complexes that are
Figure 4. The 31P NMR (CDCl3, 162 MHz) spectra of an extract
of ImpavidoÒ, 50 mg miltefosine capsules show the presence of the
singlet peak for phosphorous at d 0.7.
Figure 3. The 1H NMR (CDCl3, 400 MHz) extract of Miltefos™,
50 mg miltefosine capsules from Popular Pharmaceuticals Ltd.)
show the absence of the peaks expected if miltefosine (see Figure 2,
CH2(2¢) at 4.25, CH2(1 + 1¢) at 3.8, N(CH3)3 at 3.35) was present.
Shows the presence of a new peak for CH2 at 2.35.
Figure 5. The 31P NMR (CDCl3, 162 MHz) extract of Miltefos™,
50 mg miltefosine capsules from Popular Laboratories. The expected
singlet peak for phosphorous at d 0.7 is not present.
Figure 6. The chemical structure of miltefosine and the m/z frag-
mentation resulting in the daughter ions (183.99, 124.8, and 59.19)
resulting from the protonated mass ion [M + H]+ at m/z 430.
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zwitterionic in solution. Treatment with antimonials is associ-
ated with a range of toxicities.12,14,15 Quality control in the face
of this chemical complexity and batch-to-batch variation
is essential. During a period when there were several manu-
facturers of these antimonial drugs, issues around drug quality
and patient toxicity were reported.16 Studies by groups in India
and Brazil reported significant differences in osmolarity and
oxidation states between batches17,18 emphasising the need
for standardization and monitoring product stability by the
drug manufacturers.
In the case of miltefosine different analytical techniques of
liquid chromatography coupled to MS-MS, Fourier transform
infrared, and near-infrared spectroscopy have been previously
used to characterize poor quality drugs and were used to
determine the quality of generic Miltefos™ capsules collected
in Bangladesh.8 We used direct injection MS to determine the
molecular weight and fragmentation data to elucidate the struc-
ture, as well as NMR spectroscopy (1H and 31P) to characterize
and definitively confirm the presence of atomic nuclei in a
molecule. The molecule of miltefosine contains a phosphorous
Figure 7. (A) The full scan mass spectrum of ImpavidoÒ, 50 mg miltefosine capsules and the peaks caused by the presence of the active
ingredient at m/z 408.33 and the sodium salt m/z 430.25. Intensity of the cumulative signals over 3 minutes is 3.77 +106. (B) Showing the tandem
mass spectrometry (MS/MS) product ion scan of ImpavidoÒ, 50 mg miltefosine capsules, and the peaks caused by the presence of the active
ingredient at m/z 408.33 and the product ions at m/z 183.99 and m/z 124.8.
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Figure 8. (A) The full scan mass spectrum of Miltefos™, 50 mg miltefosine capsules from Popular Laboratories does not show peak at m/z
408.33 for the active ingredient and the origins for the peaks at 122.03 and 278.90 are unknown. Intensity of the cumulative signals over 3 minutes
is 4.56 +106. (B) The tandem mass spectrometry (MS/MS) product ion scan of Miltefos™, 50 mg miltefosine capsules from Popular Laboratories
does not show peak at m/z 408.33 for the active ingredient and the product ions at m/z 183.99 and m/z 124.8.
Table 1
Summary of results for the NMR and mass spectrometry analyses of the various miltefosine capsules*
Manufacturer Stated dose, mg Batch no. Manufacturing date Expiry date API (miltefosine) detected or not by 1H, 31P NMR and MS
ImpavidoÒ 50 8J7717 07/2006 07/2012 Detected
ImpavidoÒ 10 8H7859 08/2008 08/2012 Detected
Miltefos™ 50 SFD13 E0610 Not supplied E0610 Not detected
Miltefos™ 10 SFD12 E0610 Not supplied E0610 Not detected
NMR = nuclear magnetic resonance; API = active pharmaceutical ingredient.
*The drugs were analyzed in October 2008 at the request of The World Health Organization (WHO).
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atom and proton atoms (Figure 1). Hence, the presence of a 31P
peak on 31P NMR and proton splitting patterns on 1H NMR
seen unequivocally confirm the authenticity of the ImpavidoÒ
capsules but not of Miltefos™. Our results based on determining
the molecular structure of miltefosine, showed that the generic
product is falsified (contained no API), whereas the quality
assured product has the anticipated fragmentation patterns
on MS and the peaks on both proton and phosphorous NMR
analysis. Based on the NMR and MS spectra achieved the
compound present in these falsified capsules may be palmitic
acid. The excipients in the generic product have been reported
to be lactose and microcrystalline cellulose (a typical excipient
used in vitamins), and no stated API.8
Added to these results the bioassay analysis of extracts from
ImpavidoÒ capsules and the reference API displayed similar
and expected anti-leishmanial activity with EC50 values below
5 mg/mL against intracellular L. donovani amastigotes in vitro.
However, no significant anti-leishmanial activity was identified
against two different strains of L. donovani by the contents
from generic Miltefos™ capsules within the concentration
ranges tested. No toxicity towards PEMs was observed with
extracts from generic Miltefos™ capsules even at nominal
miltefosine concentrations of up to 100 mg/mL.
These studies emphasize the role of drug regulators in
ensuring the standards and quality of procured drugs.
CONCLUSIONS
Substandard medicines (a formulation with too little or too
much API) are a concern in countries with low standards
of quality control of the manufacturing process (non-good
manufacturing accredited status).19
The analytical chemical techniques of MS and NMR (pro-
ton and 31Phosphorous) confirmed that the generic Miltefos™
capsules (50 and 10 mg) did not contain the stated miltefosine
and is classified as falsified (no stated API found). In contrast
the analysis of the quality assured product ImpavidoÒ (50 and
10 mg) from Aeterna Zentaris GmbH (Frankfurt, Germany)
gave the anticipated ionisation patterns and spectra. The lack
of API was confirmed with the absence of bioactivity of the
generic product compared with the activity of the quality
assured product. The arsenal of techniques made available to
determine the quality of essential drugs will help to save lives
and help the fight against counterfeiters. The ability to achieve
confirmatory results using multiple techniques provides added
reassurance to the validity of the findings.
The WHO Expert Committee on the control of leishmani-
asis (2010) highlighted the importance of this fact emphasis to
the governments to only acquire drugs from prequalified pro-
ducers (see Annex at WHO TRS 949).20 The Bangladesh
government removed Miltefos from the public health clinics
(PHCs) and decided to follow WHO recommendations in
using AmbisomeÒ (10 mg/kg total dose single infusion) as the
first line treatment and is at present close to reaching the
elimination goal of < 1 case in 10,000 in most of the upazillas
after having treated more than 7,000 patients.21 Popular Lab-
oratories was taken to court and told to stop the production of
Miltefos™. However, they retained the right to import the
API from China and were made to give assurance that they
would produce a quality assured formulation of miltefosine.
National programs need quality assured drugs in their
effort to eliminate diseases such as VL. Sensitive and special-
ized chemical techniques (NMR and MS) with experienced
staff, are needed in bio-analytical laboratories in disease-
endemic countries that can be used relatively quickly to deter-
mine the quality of drugs to treat fatal diseases.
Received September 16, 2014. Accepted for publication February 23,
2015.
Published online April 20, 2015.
Acknowledgments: Harparkash Kaur is grateful to the Gates Malaria
Partnership for the provision of support for the bio-analytical facility
through an award from the Bill and Melinda Gates Foundation to the
London School of Hygiene & Tropical Medicine. Harparkash Kaur is
grateful to M. J. Perkins for his suggestion to use NMR analysis for
molecules such as miltefosine.
Authors’ addresses: Harparkash Kaur, Karin Seifert, and Simon L.
Croft, London School of Hygiene & Tropical Medicine, London,
UK, E-mails: harparkash.kaur@lshtm.ac.uk, karin.seifert@lshtm.ac
.uk, and simon.croft@lshtm.ac.uk. Geoffrey E. Hawkes and Gregory
S. Coumbarides, School of Biological and Chemical Sciences, Queen
Mary, University of London, London, UK, E-mails: g.e.hawkes@
qmul.ac.uk and gcoumbarides@gmail.com. Jorge Alvar, Drugs for
Neglected Diseases initiative (DNDi), Geneva, Switzerland, E-mail:
jalvar@dndi.org.
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
REFERENCES
1. Alvar J, Ve´lez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin
J, den Boer M, 2012. Leishmaniasis worldwide and global esti-
mates of its incidence. WHO Leishmaniasis Control Team.
PLoS ONE 7: e35671.
2. Croft SL, Olliaro P, 2011. Leishmaniasis chemotherapy–challenges
and opportunities. Clin Microbiol Infect 17: 1478–1483.
3. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C,
Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for
Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
4. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK,
Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP,
Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK,
2007. Phase 4 trial of miltefosine for the treatment of Indian
visceral leishmaniasis. J Infect Dis 196: 591–598.
5. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ, 2012.
Miltefosine: a review of its pharmacology and therapeutic effi-
cacy in the treatment of leishmaniasis. J Antimicrob Chemother
67: 2576–2597.
6. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger
A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G, 2008.
Implementation research to support the initiative on the
Table 2
Anti-leishmanial activity of the reference API and capsule extracts*
Specification Batch Exp. EC50 [mg/mL]
Reference standard 10 mg/mL D-18506 1 4.99 (4.35–5.64)
Reference standard 2 mg/mL D-18506 1 3.79 (3.74–3.83)
ImpavidoÒ 50 mg miltefosine 8J7717 1 2.68 (1.15–4.21)
ImpavidoÒ 10 mg miltefosine 8H7859 1 4.02 (2.65–5.39)
Miltefos™ 50 mg miltefosine SFD13 E0610 1 > 100
Miltefos™ 10 mg miltefosine SFD12 E0610 1 > 20
Reference standard 10 mg/mL D-18506 2 5.92 (2.15–9.68)
Reference standard 2 mg/mL D-18506 2 3.02 (1.81–4.24)
ImpavidoÒ 50 mg miltefosine 8J7717 2 2.55 (1.41–3.69)
ImpavidoÒ 10 mg miltefosine 8H7859 2 4.06 (2.63–5.48)
MiltefosÒ 50 mg miltefosine SFD13 E0610 2 > 100
MiltefosÒ 10 mg miltefosine SFD12 E0610 2 > 20
*EC50 values are given with 95% confidence intervals in brackets. The values for
Miltefos™ are representative of two samples per batch and nominal drug concentration.
CHEMICAL AND BIOASSAY TECHNIQUES FOR MILTEFOSINE 37
elimination of kala azar from Bangladesh, India and Nepal–the
challenges for diagnosis and treatment. Trop Med Int Health
13: 2–5.
7. Senior K, 2008. Global health-care implications of substandard
medicines. Lancet Infect Dis 8: 666.
8. Dorlo TP, Eggelte TA, de Vries PJ, Beijnen JH, 2012. Character-
ization and identification of suspected counterfeit miltefosine
capsules. Analyst (Lond) 137: 1265–1274.
9. Dorlo TP, Hillebrand MJ, Rosing H, Eggelte TA, de Vries PJ,
Beijnen JH, 2008. Development and validation of a quantitative
assay for the measurement of miltefosine in human plasma by
liquid chromatography-tandemmass spectrometry. J Chromatogr
B Analyt Technol Biomed Life Sci 865: 55–62.
10. Dorlo TP, Eggelte TA, Schoone GJ, de Dries PJ, Beijnen JH,
2012. A poor-quality generic drug for the treatment of visceral
leishmaniasis: a case report and appeal. PLoS Negl Trop Dis
6: e1544.
11. Seifert K, Escobar P, Croft SL, 2010. In vitro activity of anti-
leishmanial drugs against Leishmania donovani is host cell
dependent. J Antimicrob Chemother 65: 508–511.
12. Frezard F, Demicheli C, Ribeiro RR, 2009. Pentavalent antimo-
nials: new perspectives for old drugs.Molecules 14: 2317–2336.
13. Fre´zard F, Martins PS, Barbosa MC, Pimenta AM, Ferreira WA,
de Melo JE, Mangrum JB, Demicheli C, 2008. New insights
into the chemical structure and composition of the penta-
valent antimonial drugs, meglumine antimonate and sodium
stibogluconate. J Inorg Biochem 102: 656–665.
14. Sundar S, Chakravarty J, 2010. Antimony toxicity. Int J Environ
Res Public Health 7: 4267–4277.
15. Marsden PD, 1985. Pentavalent antimonials: old drugs for old
diseases. Rev Soc Brasil Med Trop 18: 187–198.
16. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM,
Berman JD, Murray HW, Singh VP, 1998. A cluster of cases
of severe cardiotoxicity among kala-azar patients treated with
a high-osmolarity lot of sodium antimony gluconate. Am J
Trop Med Hyg 59: 139–143.
17. Romero GA, de Oliveira MR, Corriera D, Marsden PD, 1996.
Physico-chemical characteristics of meglumine antimoniate in
different conditions. Rev Soc Bras Med Trop 29: 461–465.
18. Franco MA, Barbosa AC, Rath S, Dorea JG, 1995. Antimony
oxidation states in antileishmanial drugs. Am J Trop Med Hyg
52: 435–437.
19. Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R,
Pinel J, 2008. Substandard medicines in resource-poor settings:
a problem that can no longer be ignored. Trop Med Int Health
13: 1062–1072.
20. World Health Organization, 2010. Control of the Leishmaniases.
Report of a meeting of the WHO Expert Committee on the
Control of Leishmaniases, Geneva, March 22–26, 2010. WHO
Technical Report Series 949.
21. Chowdhury R, Mondal D, Chowdhury V, Faria S, Alvar J, Nabi SG,
Boelaert M, Dash AP, 2014. How far are we from visceral leish-
maniasis elimination in Bangladesh? An assessment of epidemio-
logical surveillance data. PLoS Negl Trop Dis 8: e3020.
38 KAUR AND OTHERS
